Check out DELC, they are buying up profitable psychedelicDELC News Release ORIGINAL: Why DELIC's Latest Acquisition is a Complete Game-Changer 2021-03-09 07:01 ET - News Release Whitefish, Montana--(Newsfile Corp. - March 9, 2021) - CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the leading media network dedicated to the global legal cannabis, CBD and psychedelics industries, today announced an article covering The Delic Holdings Inc. (CSE: DELC) (OTCQB: DELCF). Cannot view this image? Visit: https://orders.newsfilecorp.com/files/6612/76534_6771ff46846a99de_001.jpg The Delic Holdings Inc. To view an enhanced version of this graphic, please visit: https://orders.newsfilecorp.com/files/6612/76534_6771ff46846a99de_001full.jpg The Delic Holdings Inc. (CSE: DELC) (OTCQB: DELCF) team has been at the forefront of the cannabis industry for almost a decade. After building High Times into the giant it is today, they founded DELIC as an umbrella platform to target the nascent psychedelics industry through a combination of media properties, high-profile events, wellness clinics and more. Let's take a look at the company's latest acquisition in the psychedelics space and why it could prove to be an absolute game-changer over the coming quarters. Unique Industry Exposure DELIC recently announced the acquisition of Complex Biotech Discovery Ventures (CBDV), a licensed psilocybin and cannabis research laboratory focused on extraction, analytical testing and chemical process development. Founded by award-winning chemist Dr. Markus Roggen and UBC Professor Glenn Sammis, the high-profile lab plays an important role in the industry. Click here to learn more about the CBDV team CBDV has developed a profitable business focused on helping more than 50 blue chip psychedelics and cannabis clients with extraction optimization, analytical testing and chemical process development. After receiving a Section 56 exemption from Health Canada, enabling its lab to process Controlled Substances like psilocybin and cannabis, the company could have a lot more potential in intellectual property development. As one of just a handful of licensed psilocybin research labs in Canada, the company aims to build out an intellectual property portfolio of psilocybin analogs, novel compounds and delivery methods that could be used in future medical treatments. The company also intends to apply for a dealers' license to commercialize its research and IP. The acquisition provides DELIC with a profitable business and relationships across the psychedelics and cannabis industries along with the blue-sky potential for intellectual property development and licensing opportunities. The latter could eventually pave the way for high-margin recurring revenue as psychedelics become mainstream therapies. Building on Expertise DELIC's management team, in particular CEO Matt Stang, has a background in relationships and branding, having built High Times into the cannabis industry's preeminent media and events empire. The acquisition of CBDV opens the door to new relationships throughout the psychedelics industry while potentially adding new clients from existing relationships in cannabis. In addition to these synergies, DELIC has already built a growing media presence in the psychedelics industry that it can leverage to build out CBDV's business, including its Reality Sandwich brand and its Meet Delic wellness summit. The cross-pollination of these audiences between DELIC and CBDV could help expand near-term revenue and unlock future value. The CBDV acquisition also adds strong scientific talent to DELIC's overall management team. Dr. Roggen brings a wealth of knowledge and industry experience that's hard to find given the industry's nascent stage. This knowledge and experience could help transform other businesses that DELIC acquires and better inform its long-term strategy in the space. Looking Ahead DELIC's acquisition of Complex Biotech Discovery Ventures represents a turning point in its plan to become a leader in the space. In addition to adding a profitable business to the mix, the acquisition provides access to key blue-chip relationships across the psychedelics and cannabis industries and unique synergies for its media properties and events.